These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38772391)

  • 21. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
    Kim HK; Yoon JH; Cho JS; Kwon SY; Yoo SW; Kang HC
    Korean J Intern Med; 2020 Sep; 35(5):1164-1172. PubMed ID: 31352718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer.
    Gao H; Huang J; Dai Q; Su J
    Arch Endocrinol Metab; 2023 Mar; 67(2):197-205. PubMed ID: 36651706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
    Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
    Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
    Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
    Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
    Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
    J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Definition of the Response to Initial Therapy with Radioiodine in Patients with Differentiated Thyroid Carcinoma: Basal or Stimulated Thyroglobulin?
    Rosario PW; Mourão GF; Calsolari MR
    Horm Metab Res; 2019 Oct; 51(10):634-638. PubMed ID: 31578049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer.
    Yang X; Liang J; Li T; Zhao T; Lin Y
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1307-13. PubMed ID: 26789779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
    Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
    Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
    Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
    Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
    Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
    Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
    Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer.
    Zampella E; Piscopo L; Manganelli M; Volpe F; Nappi C; Gaudieri V; Pace L; Schlumberger M; Cuocolo A; Klain M
    Endocrine; 2023 Jun; 80(3):612-618. PubMed ID: 36692657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
    Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
    Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
    Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
    Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
    Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
    Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
    Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
    Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
    Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
    Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.